Directed arginine deiminase evolution for efficient inhibition of arginine-auxotrophic melanomas

Applied Microbiology and Biotechnology

Volumn 99, Issue 3, 2015, Pages 1237-1247

  Cheng, Feng ^a   Zhu, Leilei ^a   Lue, Hongqi ^b   Bernhagen, Jürgen ^b   Schwaneberg, Ulrich ^a,c  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c Deutsches Wollforschungsinstitut   (Germany)

Author keywords

Antiproliferation activity; Arginine deiminase; Arginine auxotrophic melanoma; Directed evolution; Lower KM value

Indexed keywords

AMMONIA; CELL CULTURE; DERMATOLOGY; DIAGNOSIS; MUTAGENESIS; ONCOLOGY; PHYSIOLOGY;

96-WELL MICROTITER PLATE; ANTI-PROLIFERATION ACTIVITIES; ARGININE DEIMINASES; DIRECTED EVOLUTION; LOWER KM VALUE; PHYSIOLOGICAL CONDITION; PSEUDOMONAS PLECOGLOSSICIDA; SITE DIRECTED MUTAGENESIS;

ARGININE;

AMMONIA; ANTINEOPLASTIC AGENT; ARGININE; ARGININE DEIMINASE; HYDROLASE;

DIRECTED MOLECULAR EVOLUTION; DRUG SCREENING; ENZYMOLOGY; GENETICS; HIGH THROUGHPUT SCREENING; HUMAN; IC50; KINETICS; MELANOMA; METABOLISM; MUTAGENESIS; PROCEDURES; PSEUDOMONAS; TUMOR CELL LINE;

AMMONIA; ANTINEOPLASTIC AGENTS; ARGININE; CELL LINE, TUMOR; DIRECTED MOLECULAR EVOLUTION; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; HYDROLASES; INHIBITORY CONCENTRATION 50; KINETICS; MELANOMA; MUTAGENESIS; PSEUDOMONAS;

EID: 84922001184     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-014-5985-z     Document Type: Article

References (31)

1. Archibald RM (1944) Determination of citrulline and allantoin and demonstration of citrulline in blood plasma. J Biol Chem 156:121–142
2. Blanusa M, Schenk A, Sadeghi H, Marienhagen J, Schwaneberg U (2010) Phosphorothioate-based ligase-independent gene cloning (PLICing): an enzyme-free and sequence-independent cloning method. Anal Biochem 406:141–146
3. Cheng PNM, Lam TL, Lam WM, Tsui SM, Cheng AWM, Lo WH, Leung, YC (2007) Pegylated recombinant human arginase (rhArg-peg(5,000mw)) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res 67:309–317
4. Das K, Butler GH, Kwiatkowski V, Clark AD Jr, Yadav P, Arnold E (2004) Crystal structures of arginine deiminase with covalent reaction intermediates; implications for catalytic mechanism. Structure 12:657–667
5. Despotovic D, Vojcic L, Prodanovic R, Martinez R, Maurer KH, Schwaneberg U (2012) Fluorescent assay for directed evolution of perhydrolases. J Biomol Screen 17:796–805
6. Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA (2002) Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 62:5443–5450
7. Galkin A, Kulakova L, Sarikaya E, Lim K, Howard A, Herzberg O (2004) Structural insight into arginine degradation by arginine deiminase, an antibacterial and parasite drug target. J Biol Chem 279:14001–14008
8. Galkin A, Lu XF, Dunaway-Mariano D, Herzberg O (2005) Crystal structures representing the Michaelis complex and the thiouronium reaction intermediate of Pseudomonas aeruginosa arginine deiminase. J Biol Chem 280:34080–34087
9. Gallego P, Planell R, Benach J, Querol E, Perez-Pons JA, Reverter D (2012) Structural characterization of the enzymes composing the arginine deiminase pathway in Mycoplasma penetrans. PLoS One 7:e47886
10. Gesztelyi R, Zsuga J, Kemeny-Beke A, Varga B, Juhasz B, Tosaki A (2012) The Hill equation and the origin of quantitative pharmacology. Arch Hist Exact Sci 66:427–438
11. Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA, Beneduce G, Castello G, De Rosa V, Petrillo A, Ascierto PA, Curley SA, Izzo F (2010) Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol 28:2220–2226
12. Gong H, Zolzer F, von Recklinghausen G, Rossler J, Breit S, Havers W, Fotsis T, Schweigerer L (1999) Arginine deiminase inhibits cell proliferation by arresting cell cycle and inducing apoptosis. Biochem Biophys Res Commun 261:10–14
13. Gong H, Zolzer F, von Recklinghausen G, Havers W, Schweigerer L (2000) Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis. Leukemia 14:826–829
14. Hudson RC, Daniel RM (1993) L-glutamate dehydrogenases: distribution, properties and mechanism. Comp Biochem Physiol B 106:767–792
15. Kelly MP, Jungbluth AA, Wu BW, Bomalaski J, Old LJ, Ritter G (2012) Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase. Br J Cancer 106:324–332
16. Kim JE, Jeong DW, Lee HJ (2007) Expression, purification, and characterization of arginine deiminase from Lactococcus lactis ssp. lactis ATCC 7962 in Escherichia coli BL21. Protein Expres Purif 53:9–15
17. Kim RH, Coates JM, Bowles TL, McNerney GP, Sutcliffe J, Jung JU, Gandour-Edwards R, Chuang FYS, Bold RJ, Kung HJ (2009) Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res 69:700–708
18. Martinez R, Jakob F, Tu R, Siegert P, Maurer KH, Schwaneberg U (2013) Increasing activity and thermal resistance of Bacillus gibsonii alkaline protease (BgAP) by directed evolution. Biotechnol Bioeng 110:711–720
19. Miyazaki K, Takenouchi M (2002) Creating random mutagenesis libraries using megaprimer PCR of whole plasmid. Biotechniques 33:1033–1038
20. Mundhada H, Marienhagen J, Scacioc A, Schenk A, Roccatano D, Schwaneberg U (2011) SeSaM-Tv-II generates a protein sequence space that is unobtainable by epPCR. Chembiochem 12:1595–1601
21. Ni Y, Schwaneberg U, Sun ZH (2008) Arginine deiminase, a potential anti-tumor drug. Cancer Lett 261:1–11
22. Ott PA, Carvajal RD, Pandit-Taskar N, Jungbluth AA, Hoffman EW, Wu BW, Bomalaski JS, Venhaus R, Pan LD, Old LJ et al (2013) Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. Invest New Drugs 31:425–434
23. Ruff AJ, Dennig A, Schwaneberg U (2013) To get what we aim for-progress in diversity generation methods. FEBS J 280:2961–2978
24. Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L (2005) The FoldX web server: an online force field. Nucleic Acids Res 33:W382–388
25. Shen LJ, Shen WC (2006) Drug evaluation: ADI-PEG-20—a PEGylated arginine deiminase for arginine-auxotrophic cancers. Curr Opin Mol Ther 8:240–248
26. Studier FW (2005) Protein production by auto-induction in high-density shaking cultures. Protein Expr Purif 41:207–234
27. Syed N, Langer J, Janczar K, Singh P, Lo Nigro C, Lattanzio L, Coley HM, Hatzimichael E, Bomalaski J, Szlosarek P et al (2013) Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. Cell Death Dis 4:e458
28. Weickmann JL, Fahrney DE (1977) Arginine deiminase from MycoplasmaArthritidis. Evidence for multiple forms. J Biol Chem 252:2615–2620
29. Zhu L, Tee KL, Roccatano D, Sonmez B, Ni Y, Sun ZH, Schwaneberg U (2010a) Directed evolution of an antitumor drug (arginine deiminase PpADI) for increased activity at physiological pH. Chembiochem 11:691–697
30. Zhu L, Verma R, Roccatano D, Ni Y, Sun ZH, Schwaneberg U (2010b) A potential antitumor drug (arginine deiminase) reengineered for efficient operation under physiological conditions. Chembiochem 11:2294–2301
31. Zuniga M, Perez G, Gonzalez-Candelas F (2002) Evolution of arginine deiminase (ADI) pathway genes. Mol Phylogenet Evol 25:429–444